Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28350219 | 0.74 | TPMT (0.60) | TPMTHSD17B10CA1CA2 | |
| SCHEMBL657937 | 0.70 | POLB (0.47) | ALDH1A1POLBL3MBTL1EPHX2RAB9A | |
| Acetic Acid SCHEMBL5904003 | 0.69 | ALDH1A1 (0.65) | ALDH1A1KMT2ATSHRSMN1; SMN2HSD17B10 | |
| Acetic Acid SCHEMBL30426001 | 0.66 | ALDH1A1 (0.50) | ALDH1A1TPMTPKMRAB9AKMT2A | |
| SCHEMBL13135971 | 0.65 | SMN1; SMN2 (0.52) | ALDH1A1POLBL3MBTL1RAB9AKMT2A | |
| SCHEMBL21102002 | 0.65 | MET (0.43) | ALDH1A1POLBL3MBTL1KMT2ASMN1; SMN2 | |
| Acetic Acid SCHEMBL5993449 | 0.65 | FKBP5 (0.73) | RAB9AKMT2ASMN1; SMN2HSD17B10 | |
| Iodobenzene SCHEMBL318185 | 0.64 | TPMT (0.48) | ALDH1A1TPMTTSHRSMN1; SMN2HSD17B10 | |
| Iodobenzene SCHEMBL20943249 | 0.64 | TPMT (0.48) | ALDH1A1TPMTTSHRSMN1; SMN2HSD17B10 | |
| Acetic Acid SCHEMBL28350220 | 0.64 | CES2 (0.46) | ALDH1A1KMT2ATSHRSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125054-A2 | PARTIALLY BIOABSORBABLE IMPLANT | CINVENTION AG (DE) | 2009-12-02 | — | — | EP | disclosed |
| EP-2120807-A2 | DEGRADABLE RESERVOIR IMPLANTS | CINVENTION AG (DE) | 2009-11-25 | — | — | EP | disclosed |
| EP-2117613-A1 | CARBON STENTS | CINVENTION AG (DE) | 2009-11-18 | — | — | EP | disclosed |
| EP-2111193-A1 | RESERVOIR IMPLANTS AND STENTS | CINVENTION AG (DE) | 2009-10-28 | — | — | EP | disclosed |
| EP-2111482-A2 | MEDICAL DEVICES WITH EXTENDED OR MULTIPLE RESERVOIRS | CINVENTION AG (DE) | 2009-10-28 | — | — | EP | disclosed |
| EP-2104472-A1 | POROUS, DEGRADABLE IMPLANT MADE BY POWDER MOLDING | CINVENTION AG (DE) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008122594-A2 | PARTIALLY BIODEGRADABLE THERAPEUTIC IMPLANT FOR BONE AND CARTILAGE REPAIR | CINVENTION AG (DE) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122596-A2 | CURABLE THERAPEUTIC IMPLANT COMPOSITION | CINVENTION AG (DE) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122595-A2 | BIODEGRADABLE THERAPEUTIC IMPLANT FOR BONE OR CARTILAGE REPAIR | CINVENTION AG (DE) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008098926-A1 | RESERVOIR IMPLANTS AND STENTS | CINVENTION AG (DE) | 2008-08-21 | — | — | WO | disclosed |
| WO-2006069677-A2 | COMBINATION COMPRISING AN AGENT PROVIDING A SIGNAL, AN IMPLANT MATERIAL AND A DRUG | CINVENTION AG (DE) | 2006-07-06 | — | — | WO | disclosed |
| EP-1478276-A4 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX THERAPEUTICS INC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1478276-A2 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | Imarx Therapeutics, Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003061593-A2 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX THERAPEUTICS, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-0619716-A1 | CONTRAST MEDIA | NYCOMED IMAGING AS (NO) | 1994-10-19 | — | — | EP | disclosed |
| WO-1993012717-A2 | CONTRAST MEDIA | COCKBAIN, JULIAN, RODERICK, MICHAELSON (GB) | 1993-07-08 | — | — | WO | disclosed |
| EP-0483278-A1 | PARTICULATE CONTRAST MEDIA | NYCOMED AS (NO) | 1992-05-06 | — | — | EP | disclosed |
| EP-0473729-A1 | CONTRAST MEDIA | NYCOMED AS (NO) | 1992-03-11 | — | — | EP | disclosed |
| WO-1991001147-A1 | PARTICULATE CONTRAST MEDIA | NYCOMED AS (NO) | 1991-02-07 | — | — | WO | disclosed |
| WO-1991001149-A1 | CONTRAST MEDIA | NYCOMED AS (NO) | 1991-02-07 | — | — | WO | disclosed |